These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36807287)

  • 1. Selumetinib in the Treatment of Orbital Plexiform Neurofibroma: A Case Report.
    Dai YL; Choi CS; Wiltsie L; Callahan AB
    Ophthalmic Plast Reconstr Surg; 2023 May-Jun 01; 39(3):e75-e78. PubMed ID: 36807287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.
    Avery RA; Dombi E; Hutcheson KA; Acosta MT; Baldwin AM; Madigan WP; Gillespie A; Fitzgibbon EJ; Packer RJ; Widemann BC
    Am J Ophthalmol; 2013 Jun; 155(6):1089-1094.e1. PubMed ID: 23453281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
    Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
    N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of selumetinib on pediatric elephantiasis neuromatosa.
    Blegen K; Ortiz-Romero SE; Juarez O; Voeller J
    Pediatr Dermatol; 2022 Sep; 39(5):764-766. PubMed ID: 35739628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
    N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment With Selumetinib for Café-au-Lait Macules and Plexiform Neurofibroma in Pediatric Patients With Neurofibromatosis Type 1.
    Guo YX; Wang HX; Wang SS; Croitoru D; Piguet V; Gao XH; Xu XG
    JAMA Dermatol; 2024 Mar; 160(3):366-368. PubMed ID: 38198164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT.
    Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC;
    Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orbital plexiform neurofibroma and high axial myopia.
    Chen JY; Muecke JS; Brown SD
    Ophthalmic Plast Reconstr Surg; 2008; 24(4):284-6. PubMed ID: 18645432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
    Anderson MK; Johnson M; Thornburg L; Halford Z
    Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acneiform rash as a side effect of selumetinib in a child with neurofibromatosis type 1 treated for inoperable plexiform neurofibromas: Good results with doxycycline.
    Volontè M; Isoletta E; Gordon S; Foiadelli T; Bassanese F; Rossi A; Marseglia GL; Savasta S; Brazzelli V
    Dermatol Ther; 2022 Aug; 35(8):e15607. PubMed ID: 35638252
    [No Abstract]   [Full Text] [Related]  

  • 11. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
    Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
    Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
    J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
    Acar S; Armstrong AE; Hirbe AC
    Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esthetic subunit approach in massive facial plexiform neurofibroma: a case report.
    de la Torre Macías M; Berenguer Frohner B; Lorca García C; de Tomás Palacios E
    Cir Pediatr; 2020 Oct; 33(4):204-208. PubMed ID: 33016662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Association of spheno-orbital dysplasia with plexiform neuroma in von Recklinghausen's neurofibromatosis].
    Khairallah M; Messaoud R; Ladjimi A; Hmidi K; Chaouch K
    J Fr Ophtalmol; 1999 Nov; 22(9):975-8. PubMed ID: 10609174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1.
    Toledano H; Dotan G; Friedland R; Cohen R; Yassur I; Toledano-Alhadef H; Constantini S; Rootman MS
    Childs Nerv Syst; 2021 Jun; 37(6):1909-1915. PubMed ID: 33751171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An unusual combination of unilateral orbital plexiform neurofibroma in a patient with oculocutaneous albinism.
    Saravanan J; Rajendraprasad A; Priyadharshni S
    Indian J Ophthalmol; 2014 Jun; 62(6):735-7. PubMed ID: 25005209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
    Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
    Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
    Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
    Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
    Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
    Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.